Ammax Biois A Private Clinical Stage Biotech Company Focused On The Development Of Innovative Cancer Therapeuticsit Leverages Its Expertise In Translational Science And Drug Development To Pursue First In Class Or Best In Class Therapeutics With Significant Market Opportunityammax Was Founded In 2020 Out Of A Partnership With Amgen Wherein Ammax Licensed An Exclusive Worldwide Right To A Monoclonal Antibody Targeting The Colony Stimulating Factor 1 Receptorcsf1R As Part Of The Transactionamgen Took A Minority Ownership In The Companyat The Core Of Ammax S Pipeline Are Amb 066 And Amb 104Ammax Is Collaborating With Md Anderson To Develop Amb 066An Mab Targeting Csf1R In Phase 2A For Treating Colorectal Cancer Minimal Residual Diseasecrc Mrd Amb 104 Is A Novel Antibody Drug Conjugate Utilizing Synaffix S Linker Payload Platform And In Development For Treating Acute Myeloid Leukemiaamland Potentially Solid Tumors Ammax Has A Very Experienced Management Teamled By Drlarry Hsuco Founder And Former Ceo Of Impax Laboratoriesinc Which He Successfully Built Into A Fully Integrated Multi Billion Dollar Publicly Traded Pharmaceutical Companywith Broad Experience Across Therapeutic Areas And Therapeutic Modalitiesthe Ammax Team Is Strong In Execution And Has Collectively Brought Multiple Blasndas And Maas To Approval And Commercializationwith A Seasoned Management Team And A Robust Pipelineammax Is Poised To Grow Into A Leading Biotech Company For More On Ammax Bio And Its Pipelineplease Visit The Company S Website Atwww Ammaxbio Com
